

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Scope for guideline update (starting 2022) Oesophago-gastric cancer: assessment and management in adults (update)

NICE is updating its guideline on [oesophago-gastric cancer: assessment and management in adults NG83](#). The guideline was originally published in January 2018. It was developed as set out in the [original scope](#).

New evidence suggests that recommendations on palliative management of luminal obstruction may need updating. Full details are set out in the August [2022 surveillance review decision](#).

The update will be developed using the methods and processes in [developing NICE guidelines: the manual](#).

1 Who the guideline update covers

The current guideline covers adults (18 years and over) with newly diagnosed or recurrent oesophago-gastric cancer. The update will focus on the palliative management of luminal obstruction for adults with cancer of the oesophagus or the gastro-oesophageal junction that is not being treated with curative intent.

Equality considerations

[The equality impact assessment for the guideline update](#) lists equality issues identified and how they have been addressed and explains why any populations were excluded from the scope.

This update will look at inequalities relating to socioeconomic factors (specifically people from low income or disadvantaged backgrounds) and people with caring responsibilities.

2 Activities, services or aspects of care covered by the guideline update

We will look at the evidence and consider making new recommendations or updating existing recommendations on:

- Palliative management of luminal obstruction for adults with cancer of the oesophagus or the gastro-oesophageal junction that is not being treated with curative intent . (Recommendations 1.5.9 to 1.5.11).

For all other areas of the guideline:

- There will be no evidence review.
- We will retain the existing recommendations but we may revise them to ensure consistency.

3 Draft review questions

We have identified the following draft review question:

What is the optimal management of luminal obstruction for adults with cancer of the oesophagus or the gastro-oesophageal junction that is not being treated with curative intent?

Draft PICO table for review question

Population	Inclusion: Adults with cancer of the oesophagus or the gastro-oesophageal junction that is not being treated with curative intent who have symptoms of luminal obstruction. No exclusion criteria
Intervention	<ul style="list-style-type: none">• Stenting (note what stent was used in the studies)<ul style="list-style-type: none">○ Self-expanding (metallic) stent○ Covered/uncovered stent○ Biodegradable stent○ Permanent/removable stent○ Mode of delivery: radiological/endoscopic○ Radioactive impregnated• Dilatation• Radiotherapy

	<ul style="list-style-type: none"> ○ Intraluminal brachytherapy ○ External beam radiotherapy ● Surgery ● Laser therapy ● Systemic anti-cancer therapy (chemotherapy, immunotherapy) ● Enteral feeding tube
Comparison	<ul style="list-style-type: none"> ● Each other ● Combinations of each of the above interventions
Outcome	<p>Follow-up times will be at <6, 6 to 12, and >12 weeks unless otherwise stated.</p> <ul style="list-style-type: none"> ● Symptom improvement (including time from intervention to improvement of symptoms). Symptoms are defined as: <ul style="list-style-type: none"> ○ Weight change/maintenance ○ Vomiting ○ Nausea ○ Aspiration ○ Cough ○ Resumption of eating ○ Swallowing (dysphagia score) ○ Pain ● Symptom recurrence (including time from intervention to recurrence of symptoms) ● Overall survival ● Re-intervention ● Technical success ● Procedure-related mortality ● Health-related quality of life ● PROMS <ul style="list-style-type: none"> ○ Chest pain ○ Gastro-oesophageal reflux ● Adverse event such as gastrointestinal (GI)-related bleeding events, perforation and pain. ● Resource use

4 Economic aspects

We will take economic aspects into account when making recommendations. We will review the economic evidence using an NHS and personal social services perspective, as appropriate.

5 NICE quality standards that may be affected by this guideline update

- [Oesophago-gastric cancer](#) (2018) NICE quality standard 176

6 Further information

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#) and [Northern Ireland Executive](#).

The guideline update is expected to be published in June 2023.

To follow the progress of the update, see the [guideline in development page](#).

Our website has information about [how NICE guidelines are developed](#).

© NICE 2023. All rights reserved. Subject to [Notice of rights](#).